4 results on '"Benning, Louise"'
Search Results
2. Donor-Derived Cell-Free DNA (dd-cfDNA) in Kidney Transplant Recipients With Indication Biopsy--Results of a Prospective Single-Center Trial.
- Author
-
Benning, Louise, Morath, Christian, Fink, Annette, Rudek, Markus, Speer, Claudius, Kälble, Florian, Nusshag, Christian, Beimler, Jörg, Schwab, Constantin, Waldherr, Rüdiger, Zeier, Martin, Süsal, Caner, and Thuong Hien Tran
- Subjects
- *
CELL-free DNA , *KIDNEY transplantation , *BIOPSY , *GERMANS , *UNIVERSITY hospitals - Abstract
Donor-derived cell-free DNA (dd-cfDNA) Identifies allograft Injury and discriminates active rejection from no rejection. In this prospective study, 106 kidney transplant recipients with 108 clinically indicated biopsies were enrolled at Heidelberg University Hospital between November 2020 and December 2022 to validate the clinical value of dd-cfDNA in a cohort of German patients. dd-cfDNA was quantified at biopsy and correlated to histopathology. Additionally, dd-cfDNA was determined on days 7, 30, and 90 post-biopsy and analyzed for potential use to monitor response to anti-rejection treatment. dd-cfDNA levels were with a median (IQR) % of 2.00 (0.48-3.20) highest in patients with ABMR, followed by 0.92 (0.19-11.25) in patients with TCMR, 0.44 (0.20-1.10) in patients with borderline changes and 0.20 (0.11-0.53) in patients with no signs of rejection. The AUC for dd-cfDNA to discriminate any type of rejection including borderline changes from no rejection was at 0.72 (95% CI 0.62-0.83). In patients receiving anti-rejection treatment, dd-cfDNA levels significantly decreased during the 7, 30, and 90 days follow-up compared to levels at the time of biopsy (p = 0.006, p = 0.002, and p < 0.001, respectively). In conclusion, dd-cfDNA significantly discriminates active rejection from no rejection. Decreasing dd-cfDNA following anti-rejection treatment may indicate response to therapy. Clinical Trial Registration: https://drks.de/search/de/trial/DRKS00023604, identifier DRKS00023604. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation.
- Author
-
Schaier, Matthias, Morath, Christian, Lei Wang, Kleist, Christian, Opelz, Gerhard, Thuong Hien Tran, Scherer, Sabine, Lien Pham, Ekpoom, Naruemol, Süsal, Caner, Ponath, Gerald, Kälble, Florian, Speer, Claudius, Benning, Louise, Nusshag, Christian, Mahler, Christoph F., Pego da Silva, Luiza, Sommerer, Claudia, Hückelhoven-Krauss, Angela, and Czock, David
- Subjects
KIDNEY transplantation ,REGULATORY B cells ,HLA histocompatibility antigens ,B cells ,OPPORTUNISTIC infections ,T cells - Abstract
Background: The administration of modified immune cells (MIC) before kidney transplantation led to specific immunosuppression against the allogeneic donor and a significant increase in regulatory B lymphocytes. We wondered how this approach affected the continued clinical course of these patients. Methods: Ten patients from a phase I clinical trial who had received MIC infusions prior to kidney transplantation were retrospectively compared to 15 matched standard-risk recipients. Follow-up was until year five after surgery. Results: The 10 MIC patients had an excellent clinical course with stable kidney graft function, no donor-specific human leukocyte antigen antibodies (DSA) or acute rejections, and no opportunistic infections. In comparison, a retrospectively matched control group receiving standard immunosuppressive therapy had a higher frequency of DSA (log rank P = 0.046) and more opportunistic infections (log rank P = 0.033). Importantly, MIC patients, and in particular the four patients who had received the highest cell number 7 days before surgery and received low immunosuppression during follow-up, continued to show a lack of anti-donor T lymphocyte reactivity in vitro and high CD19
+ CD24hi CD38hi transitional and CD19+ CD24hi CD27+ memory B lymphocytes until year five after surgery. Conclusions: MIC infusions together with reduced conventional immunosuppression were associated with good graft function during five years of follow-up, no de novo DSA development and no opportunistic infections. In the future, MIC infusions might contribute to graft protection while reducing the side effects of immunosuppressive therapy. However, this approach needs further validation in direct comparison with prospective controls. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
4. Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients.
- Author
-
Benning, Louise, Klein, Katrin, Morath, Christian, Bartenschlager, Marie, Kim, Heeyoung, Buylaert, Mirabel, Reineke, Marvin, Töllner, Maximilian, Nusshag, Christian, Kälble, Florian, Reichel, Paula, Schnitzler, Paul, Zeier, Martin, Süsal, Caner, Bartenschlager, Ralf, Schaier, Matthias, and Speer, Claudius
- Subjects
SARS-CoV-2 Delta variant ,HEMODIALYSIS patients ,BOOSTER vaccines ,COVID-19 vaccines ,IMMUNOCOMPROMISED patients - Abstract
Hemodialysis patients are at high risk for severe COVID-19, and impaired seroconversion rates have been demonstrated after COVID-19 vaccination. Humoral immunity wanes over time and variants of concern with immune escape are posing an increasing threat. Little is known about protection against the B.1.617.2 (delta) variant of concern in hemodialysis patients before and after third vaccination. We determined anti-S1 IgG, surrogate neutralizing, and IgG antibodies against different SARS-CoV-2 epitopes in 84 hemodialysis patients directly before and three weeks after a third vaccine dose with BNT162b2. Third vaccination was performed after a median (IQR) of 119 (109–165) days after second vaccination. In addition, neutralizing activity against the B.1.617.2 (delta) variant was assessed in 31 seroconverted hemodialysis patients before and after third vaccination. Triple seropositivity for anti-S1 IgG, surrogate neutralizing, and anti-RBD antibodies increased from 31/84 (37%) dialysis patients after second to 80/84 (95%) after third vaccination. Neutralizing activity against the B.1.617.2 (delta) variant was significantly higher after third vaccination with a median (IQR) ID
50 of 1:320 (1:160–1:1280) compared with 1:20 (0–1:40) before a third vaccine dose (P <0.001). The anti-S1 IgG index showed the strongest correlation with the ID50 against the B.1.617.2 (delta) variant determined by live virus neutralization (r=0.91). We demonstrate low neutralizing activity against the B.1.617.2 (delta) variant in dialysis patients four months after standard two-dose vaccination but a substantial increase after a third vaccine dose. Booster vaccination(s) should be considered earlier than 6 months after the second vaccine dose in immunocompromised individuals. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.